Base editor treats progeria in mice.

Study design: Preclinical study Population: Fibroblasts derived from people with Hutchinson-Gilford progeria syndrome and mouse models of the genetic disease Key result: Single injection of an adenine base editor (ABE) using a viral vector corrects up to 90% of the mutations in fibroblasts and ameliorates vascular disease and extends lifespan in mice Next steps: ABE could be a feasible therapeutic strategy for progeria in humans